riluzole   Click here for help

GtoPdb Ligand ID: 2326

Synonyms: Rilutek® | RP-54274 | Tiglutik® (thickened oral suspension)
Approved drug PDB Ligand
riluzole is an approved drug (FDA (1995), EMA (1996))
Compound class: Synthetic organic
Comment: Marketed formulations may contain riluzole hydrochloride (PubChem CID 6419992).
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 2
Hydrogen bond donors 1
Rotatable bonds 2
Topological polar surface area 76.38
Molecular weight 234.01
XLogP 2.28
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES Nc1nc2c(s1)cc(cc2)OC(F)(F)F
Isomeric SMILES Nc1nc2c(s1)cc(cc2)OC(F)(F)F
InChI InChI=1S/C8H5F3N2OS/c9-8(10,11)14-4-1-2-5-6(3-4)15-7(12)13-5/h1-3H,(H2,12,13)
No information available.
Summary of Clinical Use Click here for help
Used in the treatment of amyotrophic lateral sclerosis (ALS, a.k.a. motor neurone disease or MND).
Riluzole, along with amiloride and fluoxetine are repurposing candidates as potential therapeutics for secondary progressive multiple sclerosis (SPMS or late MS), having already been shown to provide neuroprotective benefit [2,6-8]. A Phase 2 clinical trial in secondary progressive MS (NCT01910259, MS-SMART trial) is ongoing (Jan 2018).
Mechanism Of Action and Pharmacodynamic Effects Click here for help
The mechanism of action of riluzole is complex, and appears to include inhibition of glutamate release, inactivation of voltage-dependent sodium channels and interference with intracellular events that follow transmitter binding at excitatory amino acid receptors. Due to the complex nature of this drug's MMOA, we do not tag a primary drug target.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT01910259 MS-SMART: Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial Phase 2 Interventional University College, London
External links Click here for help